Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids
PGX Technology continues to demonstrate ability to generate novel bioactive delivery systems for nutraceuticals, drug…
News
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
FREMONT, CA, May 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency
Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in…
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
POINT’s manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for…
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or…
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration…
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset…
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor
VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the…
Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference
SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
Conference call scheduled for 8:30 a.m. ET today MIAMI, May 13, 2022 (GLOBE NEWSWIRE) —…
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCO Presented…
SeqLL Provides First Quarter 2022 Financial Results and a Corporate Update
BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:…
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled…
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA),…
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products
Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders…
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
Expands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication…
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years
–Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV)…
Spectral Announces First Quarter Results and Provides Corporate Update
TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:…
Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference
PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience…
Abeona Therapeutics Reports First Quarter 2022 Financial Results
Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023…